Vanda's VQW-765 Misses Primary Endpoint in Phase III Social Anxiety Trial

VQW-765, an α7-nAChR partial agonist licensed by Vanda Pharmaceuticals from Novartis, missed its primary endpoint in the Phase III study VP-VQW-765-3201 (Study 3201) in adults with social anxiety disorder. Phase II results had shown numerically lower stress levels versus placebo in subjects with a history of performance anxiety, with effects strongest in women.